Adicet Bio, Inc. (ACET)
ACET Stock Price Chart
Explore Adicet Bio, Inc. interactive price chart. Choose custom timeframes to analyze ACET price movements and trends.
ACET Company Profile
Discover essential business fundamentals and corporate details for Adicet Bio, Inc. (ACET) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2018
Employees
152.00
Website
https://www.adicetbio.comCEO
Chen Schor
Description
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET Financial Timeline
Browse a chronological timeline of Adicet Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.69.
Earnings released on 13 May 2026
EPS came in at -$1.88 surpassing the estimated -$2.93 by +35.84%.
Earnings released on 12 Mar 2026
EPS came in at -$2.94 surpassing the estimated -$3.23 by +8.98%.
Stock split effective on 30 Dec 2025
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 5 Nov 2025
EPS came in at -$4.64 falling short of the estimated -$4.16 by -11.54%.
Earnings released on 7 Aug 2025
EPS came in at -$5.44 falling short of the estimated -$4.86 by -11.89%.
Earnings released on 6 May 2025
EPS came in at -$4.96 surpassing the estimated -$5.44 by +8.82%.
Earnings released on 6 Mar 2025
EPS came in at -$5.12 surpassing the estimated -$5.92 by +13.51%.
Earnings released on 6 Nov 2024
EPS came in at -$5.44 surpassing the estimated -$5.76 by +5.56%.
Earnings released on 13 Aug 2024
EPS came in at -$5.28 surpassing the estimated -$5.60 by +5.71%.
Earnings released on 14 May 2024
EPS came in at -$5.60 matching the estimated -$5.60.
Earnings released on 19 Mar 2024
EPS came in at -$11.04 surpassing the estimated -$11.52 by +4.17%.
Earnings released on 8 Nov 2023
EPS came in at -$11.36 surpassing the estimated -$11.68 by +2.74%.
Earnings released on 9 Aug 2023
EPS came in at -$12.00 falling short of the estimated -$10.88 by -10.29%.
Earnings released on 9 May 2023
EPS came in at -$11.52 surpassing the estimated -$11.84 by +2.70%.
Earnings released on 15 Mar 2023
EPS came in at -$11.52 falling short of the estimated -$8.96 by -28.57%.
Earnings released on 8 Nov 2022
EPS came in at -$8.48 surpassing the estimated -$8.96 by +5.36%.
Earnings released on 10 Aug 2022
EPS came in at -$8.96 falling short of the estimated -$7.20 by -24.44%.
Earnings released on 12 May 2022
EPS came in at $1.60 surpassing the estimated -$1.12 by +242.86%, while revenue for the quarter reached $24.99m , beating expectations by +73.64%.
Earnings released on 15 Mar 2022
EPS came in at -$7.52 falling short of the estimated -$7.04 by -6.82%, while revenue for the quarter reached $5.47m , beating expectations by +31.31%.
Earnings released on 10 Nov 2021
EPS came in at -$7.04 falling short of the estimated -$6.08 by -15.79%, while revenue for the quarter reached $3.43m , beating expectations by +18.75%.
Earnings released on 12 Aug 2021
EPS came in at -$5.44 surpassing the estimated -$8.16 by +33.33%, while revenue for the quarter reached $4.81m , beating expectations by +0.02%.
ACET Stock Performance
Access detailed ACET performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
